Tapia Luciano, Irarrázaval Sebastián
Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile; Proyecto Epistemonikos, Santiago, Chile.
Proyecto Epistemonikos, Santiago, Chile; Departamento de Traumatología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. Email:
Medwave. 2019 Dec 9;19(11):e7737. doi: 10.5867/medwave.2019.11.7736.
Acute mountain sickness is the most prevalent illness related to acute exposure to high altitude, secondary to the hypobaric hypoxia effects in our body. Acetazolamide has been traditionally used for its prevention and treatment, however, there is still controversy regarding the degree of usefulness of this medication as monotherapy.
We searched in Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from the systematic reviews, reanalyzed data of primary studies, conducted a meta-analysis and generated a summary of findings table using the GRADE approach.
We identified a systematic review that included two primary studies, both corresponding to randomized trials. We conclude that it is not possible to establish clearly whether treatment with acetazolamide reduces the symptoms of acute mountain disease or increases the risk of adverse effects, because the certainty of the existing evidence has been evaluated as very low.
急性高原病是与急性暴露于高海拔地区相关的最常见疾病,继发于我们身体中的低压缺氧效应。乙酰唑胺传统上一直用于其预防和治疗,然而,关于这种药物作为单一疗法的有用程度仍存在争议。
我们在Epistemonikos中进行了检索,Epistemonikos是最大的健康系统评价数据库,通过筛选包括MEDLINE、EMBASE、Cochrane等在内的多个信息来源来维护。我们从系统评价中提取数据,重新分析原始研究的数据,进行荟萃分析,并使用GRADE方法生成结果总结表。
我们确定了一项系统评价,其中包括两项原始研究,均为随机试验。我们得出结论,无法明确确定乙酰唑胺治疗是否能减轻急性高原病的症状或增加不良反应的风险,因为现有证据的确定性被评估为非常低。